ArticleOsteoporosis and sarcopenia2020

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis.

Satoshi Soen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.